WO2005017139A1 - Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie - Google Patents
Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie Download PDFInfo
- Publication number
- WO2005017139A1 WO2005017139A1 PCT/CN2003/001048 CN0301048W WO2005017139A1 WO 2005017139 A1 WO2005017139 A1 WO 2005017139A1 CN 0301048 W CN0301048 W CN 0301048W WO 2005017139 A1 WO2005017139 A1 WO 2005017139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thrombin
- agkistrodon acutus
- acutus
- agkistrodon
- bleeding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Agkistrodon acutus thrombin is used as a medicine for bleeding disorders
- the invention relates to a thrombin-like enzyme isolated and purified from Agkistrodon acutus snake venom, and is named Haemocoagulase Acutus (abbreviated as Hal aSe ).
- the invention relates to the use of Agkistrodon acutus thrombin for the preparation of a medicament for treating a bleeding disorder.
- bleeding is a common emergency.
- bleeding can be divided into two categories: one is a hematological or hemorrhagic disease, which is often spontaneous bleeding caused by a disorder in the body's coagulation function.
- Hemorrhagic diseases can be primary or secondary to various clinical diseases, such as thrombocytopenic purpura, hemophilia, aplastic anemia, leukemia, hypertensive encephalopathy, digestive system disease, and gastrointestinal bleeding.
- the other type is bleeding caused by injury to vascular tissue caused by injury or trauma, and its cause is simpler than that of bleeding diseases.
- each phase is a vascular phase, which is mainly manifested by vasoactive contraction, narrowing the vascular cavity, slowing blood flow, reducing bleeding or even stopping it.
- the second phase is the cell phase, that is, platelets aggregate to form platelet emboli to achieve the initial hemostasis of mechanically blocking blood vessels.
- the third phase of the plasma phase or the process of blood clotting. That is, under the action of thrombin, fibrin is changed into fibrin, and the red blood cells, white blood cells, and platelets are networked together, causing blood coagulation and promoting or strengthening the hemostatic process.
- the causes of bleeding can be divided into three types according to the pathogenesis of bleeding: one is abnormal blood vessel bleeding, that is, due to factors of the blood vessel itself, such as the inability of the blood vessel to close, and reduced capillary resistance or surrounding blood vessels Bleeding caused by abnormal tissue structure, etc .; second, blood Small plate abnormalities, such as thrombocytopenia caused by insufficient platelet production or excessive platelet destruction; third, bleeding caused by impaired coagulation mechanism.
- abnormal blood vessel bleeding that is, due to factors of the blood vessel itself, such as the inability of the blood vessel to close, and reduced capillary resistance or surrounding blood vessels Bleeding caused by abnormal tissue structure, etc .
- second blood Small plate abnormalities, such as thrombocytopenia caused by insufficient platelet production or excessive platelet destruction
- third bleeding caused by impaired coagulation mechanism.
- Hemostasis commonly used in clinical practice can also be divided into the following three categories:
- the first category is hemostatic agents that act on the walls of blood vessels.
- the pathogenesis of vascular bleeding is mainly due to increased permeability and brittleness of the blood vessel wall, loosening of connective tissue around the blood vessel, decreased vasoconstriction capacity or damage factors. Therefore, the hemostatic agents used in the clinic that act on blood vessel walls generally act on microvessels, improve their function and structure, and achieve hemostatic effects.
- the second type is a hemostatic agent that acts on platelets.
- hemostatic drugs acting on blood vessel walls and platelets have very limited adaptability and efficacy in clinical application.
- the third category is hemostatic drugs that act on the coagulation process. Due to the complexity of the normal coagulation process, the action and mechanism of this type of hemostatic drug is much more complicated than the above two types.
- Normal blood coagulation process Briefly, under the action of thrombin, fibrinogen becomes fibrin, which connects red blood cells, white blood cells, and platelets together to start blood coagulation.
- the fibrin network produced by blood coagulation must be lysed (ie, fibrinolysis) to keep the blood vessels unobstructed and maintain blood flow. This is the process of dynamic equilibrium between blood coagulation and fibrinolysis.
- thrombin and plasmin are the key target enzymes for hemostatic drugs, and promote thrombin activity or thrombin-like enzymes with thrombin-like effects. It can promote fibrinogen to become fibrin, and thus has hemostatic effect; while inhibiting fibrinolytic enzyme activity and reducing degradation of fibrin also have hemostatic effect.
- Drugs that inhibit fibrinolytic enzymes are also called antifibrinolytic drugs, and have been widely used in clinical practice, mainly for fibrinolytic system with excessive bleeding.
- antifibrinolytic drugs due to the hemostatic mechanism of these drugs, the indications must be strictly controlled in order to receive good hemostatic effects. If it is applied indiscriminately, not only the expected hemostatic effect will not be received, but even the danger of thrombosis will occur.
- thrombin that acts on or similar to thrombin is another important target enzyme for hemostatic drugs.
- Thrombin directly extracted from human or bovine plasma has been used as a hemostatic drug, but the activity after thrombin dissolution is unstable, and thrombin vein injection is listed as an absolute contraindication because it causes disseminated intravascular coagulation. Dangerous.
- the thrombin-like enzyme extracted from snake venom has a part of thrombin-like activity, but its action and action characteristics are different.
- the entire fibrinogen can be represented by ( ⁇ ⁇ , ⁇ ⁇ , ⁇ ) 2 .
- the mechanism of immediate hemostasis is to hydrolyze the A alpha chain of fibrinogen, so that fibrinogen becomes a fibrin monomer. Since Lizhi hemostasis does not activate the fibrin stabilization factor ( ⁇ factor), the fibrin monomers formed are soluble fibrin monomers. Its degradation products are quickly engulfed and metabolized by the macrophage system in the body without causing thrombosis.
- the raw material of Reptilase is Bothrops atorx. Snake venom, but the snake is not distributed in China.
- An object of the present invention is to provide a thrombin-like enzyme isolated and purified from Agkistrodon acutus snake venom, namely Haemocoagulase Acutus (abbreviated as Halase); and to provide thrombin from Agkistrodon acutus; Application in the preparation of a medicament for treating a bleeding disorder.
- a thrombin-like enzyme isolated and purified from Agkistrodon acutus snake venom namely Haemocoagulase Acutus (abbreviated as Halase)
- Halase Haemocoagulase Acutus
- the invention separates and purifies a kind of thrombin from Agkistrodon acutus snake venom in South China, and names it Haemocoagulase Acutus (abbreviated as Halase). Structure of thrombin from Agkistrodon acutus; this product is a glycoprotein composed of two subunits, connected by disulfide bonds. The N-terminal 15 amino acid sequence was determined as follows: A subunit: DCPSDWSSYE GHCYK; B subunit: DCSSGWSSYEGHCYK. Molecular weight: 29076. IDa, isoelectric point is 5. 78, containing 1. 89%-1. 95% neutral hexose.
- Haemocoagulase Acutus (abbreviated as Halase) is a thrombin-like enzyme isolated and purified from Agkistrodon acutus snake venom.
- Halase a thrombin-like enzyme isolated and purified from Agkistrodon acutus snake venom.
- the results of pharmacological and toxicological experiments show that this product has a strong hemostatic effect, and has very low toxicity. It is a safe and effective hemostatic drug.
- the N-terminal 15 amino acid sequence was determined as follows: A subunit: DCPSDWSSYE GHCYK; B subunit: DCSSGWSSYEGHCYK. The two subunits are connected by a disulfide bond.
- the results of the pharmacodynamic experiments of the Agkistrodon acutus thrombin are as follows-1.
- mice 0. Shed / Kg, 0.24U / kg and 0.12U / Kg—30 minutes after intravenous injection, the average bleeding time of tail trimming in mice was 32.79 ⁇ 10.55, 34.35 ⁇ 11.25, and 37.52 ⁇ 10.78 seconds, respectively; The bleeding time was 62.44 ⁇ 10.87 seconds; the average bleeding time of the positive control drug to stop bleeding was 40.90 ⁇ 10.74 seconds. It is shown that the Agkistrodon acutus thrombin can significantly shorten the tail bleeding time in mice.
- Agkistrodon acutus thrombin with 0.16U / Kg, 0.08U / Kg and 0.04 11 /-after intravenous injection 30111 ⁇ , Lh, 3h,
- Agkistrodon acutus thrombin was injected intravenously at 0.16U / Kg, 0.08U / Kg, and 0.04 U / Kg. 30min, lh, 3h, 6h, 12h, 24h, had no significant effect on rabbit white blood cells, red blood cells, platelet counts, and hemoglobin; Lizhi hemostasis also had no significant effect on the above four indicators.
- Agkistrodon acutus thrombin was 0.16U / Kg, 0.08U / Kg, and 0.04 1! /-After intravenous injection 3 (1 ⁇ 2: 11 1 , 1h, 3h, 6h, 12h, 24h, has no significant effect on the viscosity of whole blood at high shear rate (120mPa.s), middle shear rate (60mPa.s) and low shear rate (10mPa.s) ; Hemostasis has no significant effect on the viscosity of whole blood under the above three types of shear rates.
- Agkistrodon acutus thrombin was 0.16U / Kg, 0.08U / Kg, and 0.04 U / Kg—lh, 3h, 6h, 12h and 24h, no significant effect on the rabbit blood TXB 2 content; reptilase of TXB 2 in whole blood of rabbits also had no significant effect.
- the results of general pharmacological experiments of Agkistrodon acutus thrombin are as follows: A single intravenous injection of mice at 0.96, 0.48, and 0.24U / Kg thrombin is carried out autonomously on mice No significant effect on the number of times. Anesthesia cats received intravenous injections of Agkistrodon acutus thrombin at a dose of 0.32, 0.16 and 0.08 U / Kg, which had no significant effect on the heart rate and blood pressure of the cardiovascular system; nor did it affect the respiratory frequency and amplitude of the respiratory system Significant impact.
- Salmonella typhimurium dystrophic back mutation test, mouse testis chromosome aberration test, mouse bone marrow micronucleus test were negative.
- the results of the thrombin generation kinetics of Agkistrodon acutus is as follows: 1. Rats were given intravenous injections of 0.6, 1.2, and 2.4 Ug / Kg. The elimination half-lives t 1 / 2P were 8. 50, 9. 74, and 10. 87 h, respectively; eight 11 (31. 06, 65. 28 and 139. 39 ng. H / ml.
- the raw materials of Agkistrodon acutus thrombin and excipient dextran are dissolved in water for injection, and the volume is adjusted to a certain volume. After drying, the Agkistrodon acutus thrombin powder injection is obtained.
- the preparation is a white lyophilized powder, odorless and tasteless, easily soluble in water, and the aqueous solution is clear and transparent.
- the activity is stable at a pH of 4.0 to 7.0.
- the potency of this product is expressed by the active unit of human plasma coagulation time.
- An active unit refers to the amount of thrombin in the Agkistrodon acutus venom at 37 ° C, which promotes flocculation of standard human plasma within 60 ⁇ 20 seconds.
- Example 1 Effects of Agkistrodon acutus thrombin on bleeding tail tail cutting time in mice:
- Example 2 Impact of Agkistrodon acutus thrombin on bleeding time in rabbit ear margin veins: 30 healthy Japanese big-eared white rabbits were randomly divided into 5 groups according to body weight, 6 males and half females, 5 groups were: sharp The high-dose group of Agkistrodon acutus thrombin (0. 16U / Kg), the middle-dose group (0. 08U / kg) and the low-dose group (0. 04U / kg), the positive control was established to stop bleeding (0. 04 U / kg) The negative control was sterilized with water for injection.
- the three Agkistrodon acutus thrombin groups and the stasis hemostasis group were administered with a rabbit ear vein injection according to the experimental design dose, and the negative control was given an equal volume of sterile water for injection.
- the ear vein region of the ear tip of the sheared and sterilized rabbit ear was punctured with a disposable blood collection needle.
- the filter paper strip was gently dipped and sucked every 20 seconds until the blood No more oozing, that is, no blood stains on the filter paper strip, record the time from the beginning of bleeding until the bleeding stops, For bleeding time. Perform statistical analysis. The results are shown in Table 2.
- Twenty-four healthy Japanese big-eared white rabbits were randomly divided into 4 groups according to body weight, with 6 in each group, namely the high-dose viper thrombin thrombin group (0.16U / 1 ⁇ 2), the medium-dose group (0.08U / kg), and the low-dose group. Group (0.04U / kg) and Li hemostatic group (0.04U / kg).
- a single blood collection needle was used to puncture the middle ear artery of the rabbit, and 1 ml of blood was collected and placed in a sterilized glass test tube.
- the glass test tube was placed in a 37 ° C water bath and the time was recorded. Then tilt the test tube to see if the blood is clotting, until the blood no longer flows and is completely clotted. The judgment end point is: when the test tube is tilted 90 degrees, the blood no longer flows So far.
- the time from when blood is added to the tube and when the blood reaches the coagulation end point is the whole blood clotting time.
- Each time point after administration was compared with that before administration, and t test was performed using SSPS8.0 statistical software.
- the results are shown in Table 3.
- the results in Table 3 show that: 30 min, 1 h, 3 h, 6 h, and 12 h after thrombin from Agkistrodon acutus, all three dose groups can significantly shorten the whole blood coagulation time of rabbits. Immediate hemostasis at 30min, 1h, 3h, 6h, and 12h after administration can also significantly shorten the whole blood coagulation time of rabbits.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003292882A AU2003292882A1 (en) | 2003-08-14 | 2003-12-08 | Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03140154.6 | 2003-08-14 | ||
CNB031401546A CN1218747C (zh) | 2003-08-14 | 2003-08-14 | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005017139A1 true WO2005017139A1 (fr) | 2005-02-24 |
Family
ID=34155227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/001048 WO2005017139A1 (fr) | 2003-08-14 | 2003-12-08 | Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1218747C (zh) |
AU (1) | AU2003292882A1 (zh) |
WO (1) | WO2005017139A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008046256A1 (fr) * | 2006-10-19 | 2008-04-24 | Healthstar Medical Development Co., Ltd | Hemocoagulase |
WO2010034176A1 (zh) * | 2008-09-27 | 2010-04-01 | 康辰医药股份有限公司 | 来自尖吻蝮蛇的类凝血酶 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102757948B (zh) * | 2012-05-28 | 2014-02-05 | 广东瑞昇药业有限公司 | 尖吻蝮蛇凝血酶及其分离方法 |
CN103893770B (zh) * | 2012-12-26 | 2018-06-19 | 李和伟 | 一种冻干赋型制剂及其制备方法 |
CN105535949A (zh) * | 2015-12-28 | 2016-05-04 | 重庆骑士医院 | 巴曲酶酵母发酵中药的方法 |
EP3572507A4 (en) * | 2017-07-10 | 2020-01-15 | Sun Yat-Sen University | EXPRESSION METHOD FOR RECOMBINANT HAEMOCOAGULASE ACUTUS PROTEIN |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181421A (zh) * | 1997-11-12 | 1998-05-13 | 中国科学院上海生物化学研究所 | 尖吻蝮蛇蛇毒类凝血酶的基因序列 |
CN1306089A (zh) * | 2001-01-08 | 2001-08-01 | 中国药科大学 | 一种防治血栓性疾病的新的蛇毒类凝血酶结构及纯化 |
CN1332241A (zh) * | 2001-04-29 | 2002-01-23 | 中国科学院昆明动物研究所 | 尖吻蝮蛇毒凝血酶及其生产方法 |
CN1332242A (zh) * | 2001-04-29 | 2002-01-23 | 中国科学院昆明动物研究所 | 一种尖吻蝮蛇毒凝血酶及其生产方法 |
-
2003
- 2003-08-14 CN CNB031401546A patent/CN1218747C/zh not_active Expired - Lifetime
- 2003-12-08 WO PCT/CN2003/001048 patent/WO2005017139A1/zh active Application Filing
- 2003-12-08 AU AU2003292882A patent/AU2003292882A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1181421A (zh) * | 1997-11-12 | 1998-05-13 | 中国科学院上海生物化学研究所 | 尖吻蝮蛇蛇毒类凝血酶的基因序列 |
CN1306089A (zh) * | 2001-01-08 | 2001-08-01 | 中国药科大学 | 一种防治血栓性疾病的新的蛇毒类凝血酶结构及纯化 |
CN1332241A (zh) * | 2001-04-29 | 2002-01-23 | 中国科学院昆明动物研究所 | 尖吻蝮蛇毒凝血酶及其生产方法 |
CN1332242A (zh) * | 2001-04-29 | 2002-01-23 | 中国科学院昆明动物研究所 | 一种尖吻蝮蛇毒凝血酶及其生产方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008046256A1 (fr) * | 2006-10-19 | 2008-04-24 | Healthstar Medical Development Co., Ltd | Hemocoagulase |
US7993893B2 (en) | 2006-10-19 | 2011-08-09 | Konruns Pharmaceutical Co., Ltd | Haemocoagulase |
US8017750B2 (en) | 2006-10-19 | 2011-09-13 | Konruns Pharmaceutical Co., Ltd | Haemocoagulase |
WO2010034176A1 (zh) * | 2008-09-27 | 2010-04-01 | 康辰医药股份有限公司 | 来自尖吻蝮蛇的类凝血酶 |
US8476054B2 (en) | 2008-09-27 | 2013-07-02 | Konruns Pharmaceutical Co., Ltd. | Thrombin-like enzyme of Agkistrodon acutus |
Also Published As
Publication number | Publication date |
---|---|
CN1488399A (zh) | 2004-04-14 |
CN1218747C (zh) | 2005-09-14 |
AU2003292882A1 (en) | 2005-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5925738A (en) | Methods of production and use of liquid formulations of plasma proteins | |
FI85334C (fi) | Foerfarande foer framstaellning av en vattenbaserad, vaevnadsplasminogenaktivator (t-pa) innehaollande, koncentrerad parenterad loesning. | |
US5180583A (en) | Method for the treatment of bleeding disorders | |
US6320029B1 (en) | Methods of production and use of liquid formulations of plasma proteins | |
EP0302754B1 (en) | Stable aqueous thrombin solution | |
FI85335C (fi) | Foerfarande foer framstaellning av lyofiliserad, farmaceutisk vaevnadsplasminogenaktivator(t-pa)-komposition. | |
JP3537440B2 (ja) | 可溶性トロンボモジュリンを長期保存安定化させる方法 | |
USRE38431E1 (en) | Methods of production and use of liquid formulations of plasma proteins | |
EP0225160B1 (en) | Compositions and methods for the treatment of bleeding disorders | |
WO1997019687A9 (en) | Methods of production and use of liquid formulations of plasma proteins | |
JPH01193229A (ja) | 抗血液凝固剤 | |
WO2005017139A1 (fr) | Thrombine provenant de venin de agkistrodon acutus utilisee comme medicament pour traiter une hemorragie | |
US20070275086A1 (en) | Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy | |
JP2916947B2 (ja) | Cpb―iの安定化方法及び製剤組成物 | |
JP2000026309A (ja) | 可溶性トロンボモジュリン含有組成物 | |
JPH02218618A (ja) | トロンビン粉末製剤 | |
JPH0418032A (ja) | 組織プラスミノーゲンアクチベーター若しくはその誘導体を含有する血栓溶解剤 | |
CN100368017C (zh) | 一种具有促凝血作用的复方生物组分及其药物制剂 | |
JP2002060345A (ja) | 血液凝固能異常に係わる疾患の予防・治療剤 | |
JPH07316072A (ja) | 妊娠中毒症治療剤 | |
KR20030063454A (ko) | 혈전용해 치료요법-유도된 대출혈을 치료하기 위한활성화된 응혈 인자 ⅶ의 용도 | |
JPH0369332B2 (zh) | ||
JP3028298B2 (ja) | 経口用トロンビン製剤 | |
JPH04198196A (ja) | Cpb―iの安定化方法及びこの製剤組成物 | |
JPH07165604A (ja) | トロンビン固形組成物の安定性および再溶解性を改善する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |